All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial

Neuromyelitis optica (NMO) is a rare condition where the immune system mistakenly attacks the nerves in the eyes and spinal cord. This can cause severe vision loss, muscle weakness, and numbness. When an attack happens, quick treatment is needed to prevent lasting damage. The usual treatment for a severe attack is steroid medicine through a drip, often followed by plasma exchange, which cleans harmful antibodies from the blood. This trial compares this standard plasma exchange treatment against an antibody drug called ravulizumab (Ultomiris). Both groups will also receive steroids. Doctors want to find out whether ravulizumab helps people regain their eyesight and physical movement more effectively than plasma exchange after two months. The trial will also monitor quality of life, pain, fatigue, and nerve healing over an entire year to see which treatment offers the best overall recovery.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Les Hopitaux Universitaires De Strasbourg
Enrolment target
30
Start
12 Nov 2026

What is this study about?

Neuromyelitis optica (NMO) is a rare autoimmune disease. In NMO, the body's natural defence system gets confused and attacks healthy nerve fibres, especially the optic nerves connecting the eyes to the brain, and the spinal cord. An attack can lead to sudden, scary symptoms like blurry vision, loss of sight, severe weakness in the arms or legs, and loss of bladder control. Getting the right treatment quickly during an attack is vital to help nerves heal and stop permanent disability.

Currently, doctors treat sudden attacks with high-dose steroids given into a vein. If that is not enough, they often use a treatment called plasma exchange. Plasma exchange involves using a machine to filter the blood, removing the harmful proteins causing the attack before returning the cleaned blood to the body. While this can work well, it requires special equipment, takes several sessions, and can be physically demanding for patients.

This study is testing whether a newer targeted medicine called ravulizumab (also known by the brand name Ultomiris) works better than plasma exchange. Ravulizumab is designed to calm down a specific part of the immune system that causes nerve inflammation. By comparing ravulizumab directly against plasma exchange—with both groups also receiving steroids—researchers hope to discover which treatment helps people recover faster, protects their vision, restores movement, and improves daily quality of life.

Key takeaways

  • The trial compares a targeted drug (ravulizumab) with blood filtering (plasma exchange) for sudden NMO attacks.
  • All participants receive high-dose steroids as part of their acute treatment.
  • The main goal is to measure improvements in eyesight and movement after two months.
  • Participation lasts for 12 months and involves regular check-ups, blood tests, and MRI scans.
  • Joining is entirely optional, and you can withdraw at any point without losing standard NHS care.

Who may be eligible?

This trial is for adults aged 18 and over who have been diagnosed with neuromyelitis optica (NMO) and are currently experiencing either their very first sudden attack or a relapse of their condition.

Because the study focuses on fast treatment for sudden nerve inflammation, participants must have active symptoms affecting their vision, movement, sensation, or bladder function. People who take part need to be able to start treatment promptly so doctors can measure how well the therapy halts and reverses these symptoms.

Your clinical care team will check your overall health and medical history to make sure taking part is safe for you. If you have severe active infections or other medical conditions that make the study treatments unsuitable, you may not be able to join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with neuromyelitis optica (NMO).
  3. I am currently experiencing a new flare-up or a first attack of NMO symptoms.
  4. My attack is causing problems with my vision, mobility, sensation, or bladder control.
  5. I am able to attend regular hospital appointments and scans for up to one year.
Answer every question to see your result.

What does participation involve?

If you take part in this study, you will be randomly placed into one of two treatment groups by a computer, like tossing a coin. One group receives the medicine ravulizumab through a drip into a vein alongside steroid treatment. The other group receives the standard treatment of plasma exchange (filtering the blood through a machine) alongside steroid treatment.

Your care will begin in hospital while your attack is being treated. Over the course of 12 months, you will attend regular check-up appointments. These typically take place at 15 days, 1 month, 2 months, 6 months, and 1 year. During these visits, doctors will test your eyesight using eye charts, check your walking and nerve function, take blood samples, and ask you to fill in simple questionnaires about your energy levels, pain, and mood.

You will also have MRI scans of your brain and spinal cord at set points to see how well the inflamed nerves are healing. In total, your participation will last for about one year.

Potential risks and benefits

Taking part may mean you receive a targeted treatment that helps you recover your eyesight or mobility after a flare-up, but there is no guarantee that one treatment will work better than the other. Both treatments carry possible side effects. Ravulizumab can lower your body's ability to fight certain severe infections, such as meningococcal disease, so safety precautions and vaccinations or antibiotics may be required. Plasma exchange can cause temporary drops in blood pressure, dizziness, bleeding, or bruising where the lines are placed. Your medical team will monitor you very closely throughout the trial to keep you safe. Taking part is completely voluntary, and you are free to leave the study at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France

Common questions

What is neuromyelitis optica (NMO)?

NMO is a rare condition where the immune system attacks the nerves in the eyes and spinal cord, causing vision problems, weakness, and numbness.

Can I choose which treatment I get?

No. A computer randomly assigns you to either ravulizumab or plasma exchange so researchers can make a fair and unbiased comparison between the two.

Will both groups still get steroids?

Yes. Steroids through a drip are a standard, proven emergency treatment for NMO attacks, and all participants will receive them alongside their assigned study treatment.

How long will I be in the trial?

You will receive treatment for your flare-up right away, and your recovery will be monitored through follow-up visits over a 12-month period.

What happens if my symptoms get worse?

Your safety comes first. The hospital doctors will closely track your recovery, and if your condition worsens or does not improve, they can provide additional standard medical treatments.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.